Analysis of IDH mutation, 1p/19q deletion, and PTEN loss delineates prognosis in clinical low-grade diffuse gliomas

Background: Grades II and III gliomas have unpredictable rates of progression, making management decisions difficult. Currently, several clinical and radiological characteristics are utilized to predict progression and survival but collectively are suboptimal. Methods: In this study, we analyzed a s...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Sabha, Nesrin (VerfasserIn) , Deimling, Andreas von (VerfasserIn) , Capper, David (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: 26 January 2014
In: Neuro-Oncology
Year: 2014, Jahrgang: 16, Heft: 7, Pages: 914-923
ISSN:1523-5866
DOI:10.1093/neuonc/not299
Online-Zugang:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1093/neuonc/not299
Verlag, lizenzpflichtig, Volltext: https://academic.oup.com/neuro-oncology/article/16/7/914/1437220
Volltext
Verfasserangaben:Nesrin Sabha, Christiane B. Knobbe, Majula Maganti, Soha Al Omar, Mark Bernstein, Rob Cairns, Besmira Çako, Andreas von Deimling, David Capper, Tak W. Mak, Tim-Rasmus Kiehl, Philippe Carvalho, Evelyn Garrett, Arie Perry, Gelareh Zadeh, Abhijit Guha, and Sidney Croul

MARC

LEADER 00000caa a2200000 c 4500
001 1731778406
003 DE-627
005 20220818195044.0
007 cr uuu---uuuuu
008 200914s2014 xx |||||o 00| ||eng c
024 7 |a 10.1093/neuonc/not299  |2 doi 
035 |a (DE-627)1731778406 
035 |a (DE-599)KXP1731778406 
035 |a (OCoLC)1341359208 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a eng 
084 |a 33  |2 sdnb 
100 1 |a Sabha, Nesrin  |e VerfasserIn  |4 aut 
245 1 0 |a Analysis of IDH mutation, 1p/19q deletion, and PTEN loss delineates prognosis in clinical low-grade diffuse gliomas  |c Nesrin Sabha, Christiane B. Knobbe, Majula Maganti, Soha Al Omar, Mark Bernstein, Rob Cairns, Besmira Çako, Andreas von Deimling, David Capper, Tak W. Mak, Tim-Rasmus Kiehl, Philippe Carvalho, Evelyn Garrett, Arie Perry, Gelareh Zadeh, Abhijit Guha, and Sidney Croul 
264 1 |c 26 January 2014 
300 |a 10 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
500 |a Gesehen am 14.09.2020 
520 |a Background: Grades II and III gliomas have unpredictable rates of progression, making management decisions difficult. Currently, several clinical and radiological characteristics are utilized to predict progression and survival but collectively are suboptimal. Methods: In this study, we analyzed a set of 108 nonenhancing hemispheric grade II–III gliomas. Demographic variables, including patient age, tumor diameter, extent of resection, and performance status, were combined with molecular data (IDH mutation status [mIDH], 1p/19q codeletion, PTEN deletion, and EGFR amplification). A complete dataset for all variables was compiled for 70 of the 108 patients. Both univariable and multivariable analyses were performed to determine whether the molecular data singly or in combination offer advantages over tumor type and grade for prediction of overall survival (OS) and/or progression-free rate (PFR). Results: Patient age, clinical variables (tumor diameter, extent of resection, performance status), and pathology (tumor type and grade) were not predictive of OS or PFR. IDH mutation status alone was predictive of longer OS and PFR for the entire group of tumors; 1p/19q deletion alone was predictive of OS but not PFR. In the multivariable analysis, none of the clinical or demographic factors were predictive of OS or PFR. IDH mutation status, 1p/19q codeletion, and PTEN deletion were predictive of OS (P = .003, P = .005, P = .02, respectively). Both mIDH (P < .001) and the interaction term of 1p/19q and PTEN (P < .001) were found to be predictive of PFR. Conclusions: We conclude that the combination of mIDH, 1p/19q codeletion, and PTEN deletion may be particularly effective in discriminating good prognosis from poor prognosis hemispheric gliomas. We propose that such a scheme merits testing on larger prospective cohorts. Should our findings be confirmed, routine clinical analysis of hemispheric gliomas for mIDH, 1p/19q codeletion, and PTEN deletion would be justified. 
700 1 |a Deimling, Andreas von  |d 1959-  |e VerfasserIn  |0 (DE-588)103034115X  |0 (DE-627)735093946  |0 (DE-576)378138065  |4 aut 
700 1 |a Capper, David  |d 1979-  |e VerfasserIn  |0 (DE-588)133950751  |0 (DE-627)558829902  |0 (DE-576)300212402  |4 aut 
773 0 8 |i Enthalten in  |t Neuro-Oncology  |d Oxford : Oxford Univ. Press, 1999  |g 16(2014), 7, Seite 914-923  |h Online-Ressource  |w (DE-627)357167341  |w (DE-600)2094060-9  |w (DE-576)318041839  |x 1523-5866  |7 nnas  |a Analysis of IDH mutation, 1p/19q deletion, and PTEN loss delineates prognosis in clinical low-grade diffuse gliomas 
773 1 8 |g volume:16  |g year:2014  |g number:7  |g pages:914-923  |g extent:10  |a Analysis of IDH mutation, 1p/19q deletion, and PTEN loss delineates prognosis in clinical low-grade diffuse gliomas 
856 4 0 |u https://doi.org/10.1093/neuonc/not299  |x Verlag  |x Resolving-System  |z lizenzpflichtig  |3 Volltext 
856 4 0 |u https://academic.oup.com/neuro-oncology/article/16/7/914/1437220  |x Verlag  |z lizenzpflichtig  |3 Volltext 
951 |a AR 
992 |a 20200914 
993 |a Article 
994 |a 2014 
998 |g 133950751  |a Capper, David  |m 133950751:Capper, David  |d 910000  |d 912000  |e 910000PC133950751  |e 912000PC133950751  |k 0/910000/  |k 1/910000/912000/  |p 9 
998 |g 103034115X  |a Deimling, Andreas von  |m 103034115X:Deimling, Andreas von  |d 910000  |d 912000  |e 910000PD103034115X  |e 912000PD103034115X  |k 0/910000/  |k 1/910000/912000/  |p 8 
999 |a KXP-PPN1731778406  |e 375285555X 
BIB |a Y 
SER |a journal 
JSO |a {"origin":[{"dateIssuedDisp":"26 January 2014","dateIssuedKey":"2014"}],"name":{"displayForm":["Nesrin Sabha, Christiane B. Knobbe, Majula Maganti, Soha Al Omar, Mark Bernstein, Rob Cairns, Besmira Çako, Andreas von Deimling, David Capper, Tak W. Mak, Tim-Rasmus Kiehl, Philippe Carvalho, Evelyn Garrett, Arie Perry, Gelareh Zadeh, Abhijit Guha, and Sidney Croul"]},"type":{"bibl":"article-journal","media":"Online-Ressource"},"recId":"1731778406","id":{"doi":["10.1093/neuonc/not299"],"eki":["1731778406"]},"person":[{"given":"Nesrin","role":"aut","family":"Sabha","display":"Sabha, Nesrin"},{"family":"Deimling","role":"aut","display":"Deimling, Andreas von","given":"Andreas von"},{"given":"David","family":"Capper","role":"aut","display":"Capper, David"}],"language":["eng"],"note":["Gesehen am 14.09.2020"],"title":[{"title":"Analysis of IDH mutation, 1p/19q deletion, and PTEN loss delineates prognosis in clinical low-grade diffuse gliomas","title_sort":"Analysis of IDH mutation, 1p/19q deletion, and PTEN loss delineates prognosis in clinical low-grade diffuse gliomas"}],"physDesc":[{"extent":"10 S."}],"relHost":[{"title":[{"title":"Neuro-Oncology","subtitle":"official journal of the World Federation of Neuro-Oncology","title_sort":"Neuro-Oncology"}],"physDesc":[{"extent":"Online-Ressource"}],"part":{"extent":"10","year":"2014","pages":"914-923","issue":"7","text":"16(2014), 7, Seite 914-923","volume":"16"},"language":["eng"],"note":["Gesehen am 21.07.23"],"pubHistory":["1.1999 -"],"type":{"bibl":"periodical","media":"Online-Ressource"},"recId":"357167341","id":{"zdb":["2094060-9"],"eki":["357167341"],"issn":["1523-5866"]},"origin":[{"publisherPlace":"Oxford ; Durham, NC","dateIssuedKey":"1999","dateIssuedDisp":"1999-","publisher":"Oxford Univ. Press ; Duke University Medical Center"}],"disp":"Analysis of IDH mutation, 1p/19q deletion, and PTEN loss delineates prognosis in clinical low-grade diffuse gliomasNeuro-Oncology"}]} 
SRT |a SABHANESRIANALYSISOF2620